Leadership

Board of Directors

The Board of Directors consists of global health experts and management professionals. In addition to overseeing operations by the Leadership Team, it also resolves important business matters including approval of major rules, strategic plans, annual operational plans/budget, and funding decisions based on recommendations from the Selection Committee.
Chair & Representative Director
Hiroki Nakatani, MD, PhD, MHPEd
Former World Health Organization (WHO) assistant director-general
Visiting Professor, Keio University School of Medicine
Invited Professor at Osaka University Post Graduate School of Medicine
Minister’s Advisor on International Affairs, Ministry of Health, Labour and Welfare
Board member of National Center for Global Health and Medicine
Member of Executive Board, WHO

He served as Assistant Director-General of WHO from March 2007 to May 2015. He led the largest technical cluster comprising HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication in case of dracunculiasis (guinea worm disease). Before joining WHO, he worked at the Ministry of Health, Labour and Welfare of Japan. Dr. Nakatani received his M.D. from Keio University School of Medicine, M.H.P.Ed from the University of New South Wales, and Ph.D. from Keio University.

Vice Chair
Peter Piot, MD, PhD
Handa Professor of Global Health, and former Director, London School of Hygiene and Tropical Medicine
Visiting Professor at the National University of Singapore and the Rega Institute of the Catholic University of Leuven
Former Executive Director, UNAIDS

Peter Piot is the Handa Professor at the London School of Hygiene & Tropical Medicine, and was its Director until July 2021. He was also founding Executive Director of UNAIDS and Under Secretary-General of the United Nations (1995-2008), and has served in numerous other international and academic leadership roles. He is Special Advisor on Covid-19 to the President of the European Commission, and serves on numerous boards and has received numerous scientific and civic awards, including the Canada Gairdner Global Health Award, Robert Koch Gold medal, and Prix International INSERM, Paris. He was a 2014 TIME Person of the Year (The Ebola Fighters), and received the Prince Mahidol Award for Public Health. In 2013 he was the laureate of the Hideyo Noguchi Africa Prize for Medical Research. Professor Piot co-discovered the Ebola virus in Zaire in 1976, and led research on AIDS, women's health, and public health in Africa. He was knighted as a baron in his native Belgium, and received an honorary knighthood in the U.K., and the Grand Cordon of the Rising Sun in Japan. He has published over 600 scientific articles and 17 books.

Member
Mahima Datla
Managing Director, Biological E. Limited

Mahima Datla is Managing Director of Biological E. Over the past 13 years at BE, she has been involved in strategy and has also served as Senior Vice President of the company. She is currently responsible for strategic operations and projects. She drives Biological E.’s engagement with Government of India as well as the DCVMN and has been a GAVI board member since 2011. She is a graduate in Business Administration Management from Webster University, London.

Member
Satoshi Ezoe, MD, MPH, MPA, PhD
Director, Global Health Policy Division, International Cooperation Bureau
Ministry of Foreign Affairs

Dr. Satoshi Ezoe has worked in Japans public health and global health arena over decades. Currently, he serves as Director, Global Health Policy Division, International Cooperation Bureau, Ministry of Foreign Affairs (MOFA), since August 2020. Prior to joining MOFA, he was engaged in health care and public health policy in the Ministry of Health, Labour and Welfare of Japan, including in the areas of global health, universal health insurance system, non-communicable diseases including mental health and cancer control. He was seconded to UNAIDS Headquarters in Geneva (2009-2012). He was the first appointed Senior Coordinator for Global Health (2015-2017), where he was involved in the WHO emergency reform, coordinating health agendas for the G7 Iseshima Summit in 2016. He was most recently Counsellor of the Permanent Mission of Japan to the United Nations (2017-2020), where he was instrumental in facilitating UN General Assembly High-Level Meetings on tuberculosis (2018) and universal health coverage (2019). He is a medical doctor with PhD, and completed two masters of public health and public administration from the Harvard University.

Member
Yoshitaka Kitamura, MSc, EMBA
Director, Office of Global Health Cooperation
Ministry of Health, Labour and Welfare

Born in Japan and raised in Tokyo, New York and Hong Kong, a background that led him into Foreign Service. Currently lives in Tokyo with his wife and two sons (nine and seven). Enjoys fishing, traveling, jogging and watching movies based on actual events. After joining the Ministry of Foreign Affairs in 2001, Yoshitaka has been active in his government’s formulation of policy in such area as national security, including management of the US-Japan Alliances, and regional issues such as North Korea and China. He led the Ministry’s inter-agency coordination when Japan drastically shifted its defense budget from land to air and sea in 2010. As principal deputy to Director General on ‘strategic communication’, he helped transform Japan’s public diplomacy, at 200 plus outposts worldwide, using 3 billion USD, from 2013 to 2015. Yoshitaka’s overseas postings include New Delhi, India, the U.K., and most recently, Washington DC where, as Counselor on Congressional affairs, he engaged widely with the Leadership, Committees and Member offices in US Senate and House on trade, foreign affairs, defense (NDAA, US Japan Alliance resolution, US Japan trade deal, etc.). He also assisted Japanese companies in their dealings with Congress. Yoshitaka currently serves as director of global health issues at the headquarters of the Ministry of Health, Labour and Welfare located in Tokyo. Studied economics at Tokyo University (BA) from 1997 to 2001, studied international relations at Edinburgh University (MSc) from 2003 to 2004 and graduated from Oxford University after completing his graduate studies on foreign policy from 2004 to 2005. Earned his Executive MBA from Quantic School of Business and Technology in 2021.

Member
Daikichi Momma
Vice Chairman
Institute for International Economic Studies

Mr. Momma worked for the Ministry of Finance (MOF), Cabinet Office, and Ministry of Defense covering various responsibilities including budget, tax, finance, international finance, multilateral development banks, external aid, global health, and national securities issues. He also served as Counsellor, Permanent Delegation of Japan to OECD, and Senior Advisor to Executive Director of World Bank Group representing Japan. He has in-depth experiences and knowledge particularly in the fields of international economic cooperation and development assistance to the developing countries. Mr. Momma currently assumes several positions including Special Researcher at MOF’s Policy Research Institute, Senior Research Advisor at the Institute for International Policy Studies, Vice President of the Association of African Economy & Development Japan, Executive Director of Japan Myanmar Association, and Executive Advisor to Nippon Life Insurance Company.

Member
Ann M. Veneman, JD
Former Executive Director, UNICEF
Former Secretary, United States Department of Agriculture

Ann M. Veneman has a distinguished career in public service, including serving as Executive Director of the United Nations Children’s Fund (UNICEF) (2005-2010) and as the United States Secretary of Agriculture (2001-2005). Ms. Veneman graduated from the University of California, Davis, received a master’s degree in public policy from the University of California, Berkeley, and a juris doctor degree from the University of California, Hastings College of the Law. In 2009 she was named to the Forbes 100 Most Powerful Women list.

Supervisory Board Member
Hikaru Ishiguro, LLM
Statutory Auditor, INSPiRE Corporation

Hikaru Ishiguro serves as Statutory Auditor at INSPiRE Corporation, among other board positions. He is a graduate of the University of Tokyo and holds a LLM from Harvard Law School. Starting with Sumitomo Bank, he worked with a variety of global financial institutions and also served as President of Health and Global Policy Institute. Mr. Ishiguro became Comptroller of the University of Tokyo in 2004 and served in this role for 8 years. He is a member of the New York Sate Bar Association.

Supervisory Board Member
Saori Nakamura
Attorney at Law
Hirayama Nagareya Shirai Law Office

Saori Nakamura is an attorney at law who is a member of the Dai-ichi Bar Association in Japan and a member of the New York State Bar Association.  As an international lawyer she represents both Japanese and non-Japanese clients in a wide variety of corporate matters, including corporate governance and compliance.  Also she has been actively engaged in the pro bono matters and assisted non-profit organizations from the time of being a partner at Morrison &Foerster.  She currently belongs to Hirayama Nagareya Shirai Law Office.   She is a graduate of Kyoto University and holds a LLM from University of Michigan Law School.

Supervisory Board Member
Ko-Yung Tung, JD
Lecturer on Law, Harvard Law School,
Former Senior Vice President and General Counsel of the World Bank

Professor. Ko-Yung Tung is an international lawyer, with extensive experience in both the public and private sectors. He has served as Senior Vice President and General Counsel of the World Bank, where he was instrumental in establishing The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Secretary General of The International Centre for the Settlement of Investment Disputes (ICSID). He is Lecturer at Law at Harvard Law School where he teaches a course on international law. He practiced law at the international law firms of Morrison & Foerster, O’Melveny & Myers, and Debevoise & Plimpton. The GHIT Board benefits particularly from his expertise in international organizations, development and corporate governance. He received his undergraduate degree in physics from Harvard University and his law degree from Harvard Law School, and did graduate studies at the University of Tokyo, Faculty of Law.

Ex-Officio
Katey Einterz Owen, PhD
Director, Neglected Tropical Diseases
Pharmaceutical Industry Leadership Engagement
Bill & Melinda Gates Foundation

Dr. Katey Einterz Owen is the Director for Neglected Tropical Diseases at The Bill & Melinda Gates Foundation and has responsibility for the Gates Foundation / Pharmaceutical Industry CEO Roundtable. Katey has end-to-end responsibility for the Gates Foundation’s investment portfolio in controlling, eliminating, and eradicating the diseases of the London Declaration. This includes active investment in lymphatic filariasis, onchocerciasis, schistosomiasis, STH, trachoma, Guinea Worm, HAT, and visceral leishmaniasis, diseases that collectively put at risk more than one billion people in the world. The portfolio funds projects with global private and public partners across the value chain, from research and innovation to project demonstration through on-the-ground delivery of interventions in Africa and Asia. In her role with the CEO Roundtable, Katey facilitates regular interaction between the CEOs of pharmaceutical organizations with Mr. Gates, resulting in joint work in global health that can most effectively be accomplished by the organizations together. Previously, Katey was the Deputy Director for Vaccine Development at the Gates Foundation. She joined BMGF in 2013 from the pharmaceutical industry. She combines a technical end-to-end view of product development and quality manufacturing, with a commercial understanding of the for-profit pharmaceutical business, coupled to practical solutions for funding and delivery in LMICs, all with a solutions-focused mindset and disposition. Prior to joining the pharmaceutical industry, Katey carried out academic research on influenza at the National Institute for Medical Research in Mill Hill (London). She earned her PhD in molecular virology from Purdue University.

Ex-Officio
Richard Seabrook, PhD, MBA
Independent Senior Advisor, Innovations, Wellcome
CEO 360Biomedical Ltd
Royal Society Entrepreneur in Residence University of Bristol

Currently chair PREPARE Trial Steering Group, member of the International Polycap Cardiovascular (TIPs3) Trial Steering Group, Advisory Board member for the Structural Genomics Consortium and non executive director NRG Therapeutics Ltd. Also a co-founder for the start-up company Vivifi Biotech Ltd. He advises the British Heart Foundation, Parkinson’s UK and the Association of Medical Research Charities. Previously he led the Business Development Team at Wellcome, where he was a non-executive director for both Wellcome Trust Trading Ltd and Wellcome International Ltd and a board observer for the Wellcome Trust Sanger Institute.

Committee

Standing Committees of the Board are established to serve specific functions.

Audit Committee

Reviews audit reports with the auditor and ensures that appropriate internal controls are in place.

Executive Review Committee

Reviews CEO and COO performance and makes recommendations regarding annual compensation and bonuses to the Board of Directors.

Governance Committee

Confirms whether GHIT is being managed in accordance with its policies. Creates succession plans for the Chair of the Board of Directors and CEO. Proposes Board member succession plans and priorities for future composition to the Board of Directors and the Council.

Portfolio and Launch Strategy Committee

Helps to review GHIT’s portfolio and determine strategy for future Requests for Proposals. Review and critique strategies that solidify introductory plans for new products.

Remuneration Committee

Provides the Board of Directors with its remunerations of directors excluding the Executive Director who is concurrently serving as the CEO.